Figure 5

Anti-tumor activity resides predominantly in the subset of tDLN cells that were initially CD62L^- and remained CD62L^- after B/I activation and expansion in culture. Tumor-sensitized lymphocytes were separated by CD62L phenotype, both before and after B/I activation, resulting in 5 groups: unsorted B/I activated tDLN, CD62L⁺ cells that remained CD62L⁺ after B/I activation and expansion (CD62L⁺ → CD62L⁺ ), CD62L⁺ cells that downregulated CD62L after B/I (CD62L⁺ → CD62L^- ), CD62L^- cells that remained CD62L^- after B/I (CD62L^- →CD62L^- ), and CD62L^- cells that upregulated CD62L expression after B/I (CD62L^- → CD62L⁺ ). Mean tumor sizes ± SE are charted over time. Numbers to the right indicate the number of mice with complete tumor regression per total number of mice. A) 4T1 tumor-bearing mice (3 days after inoculation of 50,000 4T1 cells) were either untreated, treated with CYP alone or treated with CYP + AIT (on day 4) with unfractionated or twice fractionated cells, as described above. 20 × 10⁶ whole, 20 × 10⁶ (CD62L⁺ → CD62L^-), 4 × 10⁶ (CD62L^- → CD62L⁺), or 8 × 10⁶ (CD62L^- → CD62L^- ) cells were transferred, variations due to the limited number of cells available in subsets. The unseparated, (CD62L^- → CD62L⁺), and (CD62L^- → CD62L^- ) groups were significantly different from the untreated, CYP only, and (CD62L⁺ → CD62L^-) groups [F(5,32) = 22.9156, P < 0.0001]. B) 4T1 tumor-bearing mice (3 days after inoculation of 100,000 4T1 cells) were either untreated, treated with CYP alone or treated with CYP + AIT (on day 4) with 15 × 10⁶ unfractionated or twice fractionated cells (except for the (CD62L^- → CD62L⁺) group, which received 10 × 10⁶ cells). The unseparated and (CD62L^- → CD62L^- ) groups were significantly different from the untreated, CYP only, (CD62L^- → CD62L⁺ ), and (CD62L⁺ → CD62L^- ) groups [F(6,37) = 17.7496, P < 0.0001].